CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.18 USD | -9.23% |
|
-11.94% | -59.73% |
Financials (USD)
| Sales 2024 * | 15.52M | Sales 2025 * | 7.2M | Capitalization | 49.44M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M | Net income 2025 * | -69M | EV / Sales 2024 * | 3.19 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.87 x |
| P/E ratio 2024 * |
-0.94
x | P/E ratio 2025 * |
-0.96
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -9.23% | ||
| 1 week | -11.94% | ||
| Current month | -11.28% | ||
| 1 month | -27.16% | ||
| 3 months | -54.26% | ||
| 6 months | -55.13% | ||
| Current year | -59.73% |
1 week
1.16
1.35
1 month
1.161.66
Current year
1.163.06
1 year
1.169.77
3 years
1.169.77
5 years
1.169.77
10 years
1.169.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +3.46% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 1.19 | -8.46% | 250,409 |
| 24-06-03 | 1.3 | -2.26% | 133,235 |
| 24-05-31 | 1.33 | +1.53% | 175,475 |
| 24-05-30 | 1.31 | +1.55% | 146,675 |
| 24-05-29 | 1.29 | -3.73% | 188,952 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.19
USD
Average target price
7.6
USD
Spread / Average Target
+538.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -59.73% | 49.44M | |
| +16.73% | 123B | |
| +13.04% | 107B | |
| -5.80% | 24.01B | |
| +1.98% | 22.59B | |
| -10.09% | 18.16B | |
| -40.52% | 16.84B | |
| -14.00% | 16.23B | |
| +1.18% | 13.43B | |
| +24.18% | 11.32B |
- Stock Market
- Equities
- CARM Stock
